176 related articles for article (PubMed ID: 34588225)
21. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.
Kihara M; Ikeda Y; Takagi N; Fujita H; Shibata K; Masumori S; Shiratori K; Umemura S; Shionoiri H; Ishii M
Intensive Care Med; 1995 Apr; 21(4):348-51. PubMed ID: 7650258
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
27. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
[TBL] [Abstract][Full Text] [Related]
29. Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults.
Mahmoudi L; Mohammadpour AH; Niknam R; Ahmadi A; Mojtahedzdeh M
Anaesth Intensive Care; 2014 Mar; 42(2):228-33. PubMed ID: 24580389
[TBL] [Abstract][Full Text] [Related]
30. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
32. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.
Maller R; Emanuelsson BM; Isaksson B; Nilsson L
Scand J Infect Dis; 1990; 22(5):575-9. PubMed ID: 2259867
[TBL] [Abstract][Full Text] [Related]
33. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
Illamola SM; Colom H; van Hasselt JG
Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
[TBL] [Abstract][Full Text] [Related]
34. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
36. Determinants of amikacin first peak concentration in critically ill patients.
Boidin C; Jenck S; Bourguignon L; Torkmani S; Roussey-Jean A; Ledochowski S; Marry L; Ammenouche N; Dupont H; Marçon F; Allaouchiche B; Bohé J; Lepape A; Goutelle S; Friggeri A
Fundam Clin Pharmacol; 2018 Dec; 32(6):669-677. PubMed ID: 29660162
[TBL] [Abstract][Full Text] [Related]
37. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
[TBL] [Abstract][Full Text] [Related]
38. Amikacin population pharmacokinetics among paediatric burn patients.
Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
[TBL] [Abstract][Full Text] [Related]
39. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
[TBL] [Abstract][Full Text] [Related]
40. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
Sridharan K; Abbasi MY; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
